Mechanistic insights into vincristine interactions with azoles and dasatinib: Implications for neurotoxicity in paediatric patients using physiologically based pharmacokinetic modelling
British Journal of Clinical Pharmacology · 10.11.2026
DOI: 10.1002/bcp.70915 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 10.11.2026. Verfasst von Yawen Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Aims
This study aimed to investigate the mechanisms and pharmacokinetic consequences of vincristine (VCR) drug–drug interactions (DDIs) with azole antifungals and dasatinib (DAS).
Methods
In vitro enzyme and transporter assays were conducted to characterize VCR metabolism and inhibition by posaconazole (POS), voriconazole (VRZ), fluconazole (FLZ) and DAS. Paediatric physiologically based pharmacokinetic (PBPK) models were developed using in vitro parameters and further refined using empirical Bayesian estimates from a VCR population pharmacokinetic model. Cytotoxicity was assessed using dorsal root ganglion (DRG) cell assays.
Results
POS competitively inhibited CYP3A4 and CYP3A5 ( Kᵢ = 1.62 and 1.35 μM) and P‐gp ( IC 50 = 7.72 μM), whereas VRZ competitively inhibited CYP3A4 and CYP3A5 ( Kᵢ = 8.87 and 4.22 μM) and additionally exhibited mechanism‐based inhibition of CYP3A4 (K I = 16.24 μM, k inact = 0.0263 min −1 ). FLZ showed weak inhibition of CYP3A4 and CYP3A5 (Kᵢ > 60 μM), whereas DAS showed moderate inhibition ( Kᵢ = 1.99–4.42 μM). The simulated VCR clearance was also approximately halved (CL = 0.59 vs . 0.33 L/h/kg) when co‐administrated with POS. Moreover, PBPK modelling indicated that intravenous POS and VRZ increased VCR AUCs by more than twofold. In vitro DRG cell assays demonstrated a concentration‐dependent potentiation of VCR‐induced cytotoxicity by POS.
Conclusions
Collectively, these PBPK model predictions suggest that POS and VRZ may represent high‐risk perpetrators of VCR DDIs in children and may help guide future dose optimization and toxicity management, pending confirmation in prospective clinical studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Pharmaceutical Administration, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Infection, Immunity, Inflammation Section, UCL Institute of Child Health, London, UK.
ORCID-Profile: Yawen Yuan, Joseph F Standing
Förderung
- National Natural Science Foundation of China (NSFC)
Zitieren
APA
Yuan, Y., Wu, J., Cao, J., Xu, B., Zheng, M., & Standing, J. F. (2026). Mechanistic insights into vincristine interactions with azoles and dasatinib: Implications for neurotoxicity in paediatric patients using physiologically based pharmacokinetic modelling. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70915
Vancouver
Yuan Y, Wu J, Cao J, Xu B, Zheng M, Standing JF. Mechanistic insights into vincristine interactions with azoles and dasatinib: Implications for neurotoxicity in paediatric patients using physiologically based pharmacokinetic modelling. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70915
BibTeX
@article{Yuan2026,
author = {Yuan, Yawen and Wu, Juan and Cao, Jing and Xu, Bulong and Zheng, Mei and Standing, Joseph F},
title = {Mechanistic insights into vincristine interactions with azoles and dasatinib: Implications for neurotoxicity in paediatric patients using physiologically based pharmacokinetic modelling},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70915}
}
EUVIMED